P/E ratio for Orchard Therapeutics (ORTX)
P/E ratio as of April 2024 (TTM): -2.69
According to Orchard Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.69355. At the end of 2022 the company had a P/E ratio of -0.3136.
P/E ratio history for Orchard Therapeutics from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.3136 | -71.97% |
| 2021 | -1.12 | -60.33% |
| 2020 | -2.82 | -64.11% |
| 2019 | -7.86 | 783.45% |
| 2018 | -0.8894 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | -0.4995 | -81.46% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | 0.00% | 🇬🇧 UK |
 Novavax NVAX | -0.6022 | -77.64% | 🇺🇸 USA |
 Novocure
NVCR | -6.54 | 142.91% | Jersey |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.